Join BOPA
Back to news articles

BOPA-PRUK Research Award 2017 – now open for applications

By Steve Williamson on 9th January 2017

BOPA and Pharmacy Research UK (PRUK) are delighted to announce that the funding round for 2017 is now open and applicants have until the 3rd May 2017 to submit their application.

The BOPA-PRUK Research Award (jointly funded by the British Oncology Pharmacy Association (BOPA) and PRUK) is designed for pharmacy professionals in oncology and haematology to undertake research projects in translational and health service related to oncology and haematology pharmacy, with a focus on patient benefit.

For more information, appropriate application forms and guidance documents please see the PRUK Awards and Bursaries web page or contact [email protected].

 

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article